Next Generation Ophthalmic Drug Delivery Summit

Memo

The inaugural Next Generation Ophthalmic Drug Delivery Summit is coming to San Francisco in January 2023, to help ophthalmic drug developers overcome translational challenges of developing novel long-lasting ophthalmic therapies via novel delivery methods to reduce healthcare burden and increase patient compliance. Join 18+ expert speakers from the likes of Genentech, Aerie Pharmaceuticals, Novartis, Clearside Biomedical, Janssen, Eyevensys, and EyePoint Pharmaceuticals to overcome your translational challenges and enhance extended drug efficacy while avoiding systemic and local adverse effects. Don't miss your only opportunity for an industry-specific meeting for networking and sharing extended-duration therapies with the ophthalmic drug development community. URLs:Tickets: https://go.evvnt.com/1374925-2?pid=5569 Brochure: https://go.evvnt.com/1374925-3?pid=5569  Date and Time: On Tue, 24 Jan 2023 09:00 - Thu, 26 Jan 2023 16:15 Venue details: Hyatt Centric Fisherman's Wharf San Francisco, 555 North Point Street, San Francisco, California, 94133, United States Prices:Drug Developer Pricing - Conference + 2 Workshops: USD 4297.00,Drug Developer Pricing - Conference + 1 Workshop: USD 3648.00,Drug Developer Pricing - Conference Only: USD 2999.00,Solution Provider Pricing - Conference + 2 Workshops: USD 5097.00,Solution Provider Pricing - Conference + 1 Workshop: USD 4348.00,Solution Provider Pricing - Conference Only: USD 3599.00 Speakers: Anna Abolian, Medical Director, Clinical Development, REGENXBIO, Anneli Savinainen,Vice President, Head of Preclinical Research and Development, Aura Biosciences Inc, Ashwath Jayagopal, Chief Scientific Officer, University of Vanderbilt, David Tanzer, Chief Medical Officer and Executive Vice President - Clinical and Medical Affairs, Occuterra Therapeutics, Hemant Khanna, VP - Ocular Research, IVERIC bio, Justin Creel, Vice President - Device Development, Gyroscope Therapeutics, Melissa Liew, Vice President, Global Translational Medicine, Head- Ophthalmology, Novartis AG, Michael Stewart, Professor and Chairman of Ophthalmology, Mayo Clinic, Mitchell de Long, Vice President - Chemistry, Aerie Pharmaceuticals, Patricia Zilliox, President and Chief Executive Officer, Eyevensys, Raj Singh, Thakur Chief Medical Officer, Executive Vice President - Clinical and Medical Affairs, Re-Vana Therapeutics Ltd, Ronald Yamamoto, Chief Scientific Officer, Oxular Ltd., Ruslan Grishanin, Executive Director - Nonclinical Development, Adverum, Said Saim, SVP and Chief Technology Officer, EyePoint Pharmaceuticals, Samarendra Mohanty, Chief Scientific Officer and President, Nanoscope Technologies LLC, Shamika Gune, Group Medical Director, Ophthalmology, Genentech, Stela Vujosevic, Head of Medical Retina Service, Ospedale San Giuseppe, Stephen Poor, Director - External Innovation and Translational Biomarkers, Novartis AG, Thomas Ciulla, Chief Medical Officer and Chief Development Officer, Clearside Biomedical